TmBU chemo before stem cell transplant for high-risk leukemia
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This clinical trial tests a new combination of chemotherapy drugs (called TmBU) before a stem cell transplant for people with high-risk or relapsed acute leukemia. The goal is to see if this conditioning regimen works better and is safe for patients who need a transplant.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have acute myeloid leukemia (AML) or acute lymphoblastic leukemia (ALL) that is high-risk, has come back after treatment, or is not responding to standard therapy.
- Your age should be between 15 and 65 years old.
- Your heart, kidneys, and liver must be working well enough for a stem cell transplant.
- You should not have an active infection like HIV, hepatitis B or C, or uncontrolled other infections.
- You must not have another cancer that was treated in the last 3 years, and you should not have serious brain or nerve conditions like seizures or stroke.
- You should be willing to use contraception if you could become pregnant or father a child.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug combination (SHR2554 plus azacitidine) given before a stem cell transplant to treat aggressive leukemia, myelodysplastic syndrome, or lymphoblastic leukemia. The goal is to reduce cancer cells before transplant and improve outcomes.
This trial tests a new drug combination (SHR2554 and azacitidine) given before a stem cell transplant to treat aggressive leukemias, lymphomas, or bone marrow disorders. The goal is to improve survival and reduce cancer recurrence in patients with high-risk or hard-to-treat disease.
This trial tests a new type of radiation therapy called automated total marrow and lymphoid irradiation (TMLI) given before a stem cell transplant. It's designed to treat blood cancers like leukemia and myelodysplastic syndrome by destroying cancer cells and preparing the body to accept donor stem cells.
This trial tests a chemotherapy conditioning regimen called TBF before a haploidentical stem cell transplant (using cells from a partially matched family donor) in adults ages 55–75 with acute myeloid leukemia that has responded well to initial treatment. The goal is to see if this approach helps older patients tolerate transplant and achieve long-term remission.
This trial tests a conditioning regimen (total marrow and lymphoid irradiation, fludarabine, and melphalan) before a donor stem cell transplant for people with high-risk myelodysplastic syndrome or acute myeloid leukemia. It aims to reduce side effects while still controlling the disease.
This trial tests which chemotherapy combination (BuCy or TBICy) works better for people with T-cell acute lymphoblastic leukemia getting their first stem cell transplant. The goal is to find the safer and more effective approach.
Hear when a new Acute Myeloid Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.